With this causality and given that 5% of NSCLC tumors have mutations in PTPRH, and an estimated 235,000 cases of lung cancer occurring yearly within the United States, over 10,000 patients who present with PTPRH mutations could potentially benefit from EGFR targeted TKI therapy. This evidence concerns the gene PTPRH and lung carcinoma.